<DOC>
	<DOCNO>NCT02059759</DOCNO>
	<brief_summary>The primary objective evaluate ALS patient regulatory T cell early response two low-doses IL-2 1 2 MIU per day one course 5 consecutive day comparatively placebo .</brief_summary>
	<brief_title>Immuno-modulation Amyotrophic Lateral Sclerosis- Phase II Study Safety Activity Low Dose Interleukin-2</brief_title>
	<detailed_description>This phase II study ld-IL-2 therapeutic agent ALS aim define activity safety range dose subsequent use best dose phase II/III trial . For ethical reason , ld-IL-2 must test add-on therapy riluzole hence patient need treat riluzole least three month prior entry . A randomized ( 1:1:1 ) , placebo-controlled , double-blind , parallel group trial carry assess ld-IL-2 activity regulatory T cell immuno-inflammatory marker ALS patient treat 3 month ( 5 day every four week repeat three time ) . The secondary objective study : A . To evaluate maintenance Tcell response three repeat 5-day course one course every four week 12 week . B . To evaluate safety ld-IL-2 therapy ALS population , overall follow-up 6 month ( 15 week last administration ) ; C. To evaluate functional change throughout study ; D. To evaluate change pre-defined blood cytology parameter , blood biomarker axonal damage .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>The patient correctly inform The patient must give his/her inform signed consent . The patient must insure beneficiary health insurance plan . The patient least 18 year old less 75 year old Probable , laboratorysupported probable definite ALS define El Escorial Revised ALS diagnostic criterion ( accord Airlie House Conference 1988 ) Stable riluzole treatment 3 month liver function test result &lt; 2ULN Disease duration ≤ 5 year Vital capacity ≥ 70 % normal Ability swallow without requirement nasogastric PEG feeding Agreement patient use adequate method contraception throughout study 2 week post study visit The patient available willing participate seven study visit occur CHU within next six month The patient participate another interventional study Within past three month , patient participate another interventional The patient exclusion period determine previous study The patient judicial protection The patient adult guardianship The patient refuse sign consent It impossible correctly inform patient Other life threaten disease Presence contraindicate concomitant treatment potential neuroprotective benefit ( see section 11.2 protocol ) Presence tracheostomy noninvasive ventilation Use Percutaneous endoscopic gastrostomy ( PEG ) nasogastric tube Presence clinical infection ( treat untreated ) Positive serology CMV , EBV ( confirm viral load ) , HIV Vaccination within 8 week prior first experimental dose Other disease preclude functional assessment Cancer within past 5 year ( except stable nonmetastatic basal cell skin carcinoma situ carcinoma cervix ) Severe cardiac pulmonary disease Documented autoimmune disorder except asymptomatic Hashimoto thyroiditis Women child bear age without contraception pregnant breast feed Any clinically significant laboratory abnormality ( except cholesterol , triglyceride glucose )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>low-dose interleukin 2</keyword>
</DOC>